Cingulate Reports Q3 Results, FDA Accepts NDA for CTx-1301, May 2026 PDUFA Date.
ByAinvest
Thursday, Nov 13, 2025 8:10 am ET1min read
CING--
• Cingulate Inc. announces Q3 financial results and corporate highlights • FDA accepts NDA for CTx-1301; PDUFA date set for May 31, 2026 • Once-daily, extended-release therapy designed to optimize ADHD treatment • Commercial supply agreement executed • Industry veteran Bryan Downey named Chief Commercial Officer
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet